| 产品详情 |
| Edit |   |
|---|
| Product Name | EG-VEGF, Active, Recombinant, Human |
|---|
| Description | Purity ~95% (SDS-PAGE, HPLC). Endotoxin: ≤0.1ng/ug. Embryonic vascular system undergoes a series of complex, highly regulated series of events involving differentiation, migration and association of primitive endothelial cells. This process is termed vasculogenesis. Study of tumor angiogenesis has led to the identification of several proteins including basic fibroblast growth factor (bFGF) and vascular endothelial growth factor. VEGF acts by interacting with a family of largely endothelial-specific receptor tyrosine kinases that includes VEGFR-1 (flt-1), VEGFR-2 (flk- 1/KDR), and VEGFR-3/Flt-4. Disruption of VEGFRs interferes with differentiation of endothelial cells and it is lethal for the embryo. VEGF is a heparin-binding glycoprotein that is secreted as a homodimer of 45kD. There are several splice variants of VEGF-A. The major ones include: 121, 165, 189 and 206aa, each one comprising a specific exon addition. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has hepar |
|---|
| Size | 5ug |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | EG-VEGF, Active, Recombinant, Human (Prokineticin-1, Endocrine-gland-derived Vascular Endothelial Growth Factor, Mambakine, PROK1, UNQ600/PRO1186) |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | V2110-06 |
|---|
| Price | |
|---|
| Order / More Info | EG-VEGF, Active, Recombinant, Human from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|